INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2018

In a phase 1 study, oral nicotinamide boosted circulating NAD+ metabolites, was well tolerated, and was associated with less acute kidney injury.

In critically ill patients, an elevated urinary quinolinate/tryptophan ratio predicted acute kidney injury (AKI) and other adverse outcomes. A phase 1 placebo-controlled study of oral nicotinamide (NAM) demonstrated a dose-related increase in circulating NAD+ metabolites. Oral NAM was well tolerated and was associated with less AKI. The study also examined murine models of AKI.

Study type
Phase 1 placebo-controlled study and observational analyses
Who was studied
Critically ill patients and phase 1 trial participants (exact sample sizes not stated)
What was measured
Urinary quinolinate/tryptophan ratio, AKI and adverse outcomes, circulating NAD+ metabolites, NAM tolerability

THE PAPER

De novo NAD+ biosynthetic impairment in acute kidney injury in humans.

Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J, Lerner A, Kher A, Kim SH, Khoury CC, Herzig SJ, Trovato ME, Simon-Tillaux N, Lynch MR, Thadhani RI, Clish CB, Khabbaz KR, Rhee EP, Waikar SS, Berg AH, Parikh SM. Nat Med, 2018.

PubMed 30127395 ↗DOI 10.1038/s41591-018-0138-z ↗

Nutrients & adequacyKidney health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.